Worthley Daniel L, Smith Alicia, Bampton Peter A, Cole Stephen R, Young Graeme P
Department of Gastroenterology and Hepatology, Flinders Medical Centre, South Australia, Australia.
Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1079-83. doi: 10.1097/01.meg.0000231754.35340.fa.
Population-based colorectal cancer screening by fecal occult blood testing reduces cancer-specific mortality. Current guidelines recommend this strategy for average risk individuals. This study investigated the prevalence of higher-than-average risk characteristics, and rate of prior colonoscopy, in participants in fecal occult blood test screening programs.
Randomly selected individuals aged 50-74 years in urban Adelaide were offered free fecal occult blood test screening by mail, without prior knowledge of their medical status. Each invitation included a questionnaire to record the prevalence of higher-than-average risk characteristics related to symptoms, family history or comorbidity, as well as prior colonoscopy. The definition of average risk was taken from updated guidelines published by the US Multisociety Task Force on Colorectal Cancer.
Of 2538 responses analyzed, 425 individuals had had a colonoscopy within the last 5 years, 106 fulfilled family history criteria for an initial screening colonoscopy, 209 had past polyps and 26 had had colorectal cancer. Eighty-three reported recent rectal bleeding. By current guidelines, 23% of the screened population did not warrant fecal occult blood test, because either prior colonoscopy rendered it unnecessary or particular patient characteristics made colonoscopy a more appropriate initial investigation.
Fecal occult blood test screening programs capture a sizeable number of higher-than-average risk individuals that may warrant colonoscopic rather than fecal occult blood test screening. Other participants have had a recent colonoscopy and probably warrant a delay in screening. Mass population fecal occult blood test-based screening programs need to more effectively target those at average risk and should divert those of higher or lower risk to more individualized assessment.
通过粪便潜血检测进行基于人群的结直肠癌筛查可降低癌症特异性死亡率。当前指南推荐将此策略应用于平均风险个体。本研究调查了粪便潜血检测筛查项目参与者中高于平均风险特征的患病率以及既往结肠镜检查率。
在阿德莱德市区随机选取年龄在50 - 74岁的个体,通过邮件提供免费的粪便潜血检测筛查,且事先不了解他们的健康状况。每份邀请函都包含一份问卷,用于记录与症状、家族史或合并症相关的高于平均风险特征的患病率,以及既往结肠镜检查情况。平均风险的定义取自美国结直肠癌多学会工作组发布的更新指南。
在分析的2538份回复中,425人在过去5年内进行过结肠镜检查,106人符合初始筛查结肠镜检查的家族史标准,209人有既往息肉史,26人曾患结直肠癌。83人报告近期有直肠出血。按照当前指南,23%的筛查人群无需进行粪便潜血检测,因为要么既往结肠镜检查使其不必要,要么特定的患者特征使结肠镜检查成为更合适的初始检查。
粪便潜血检测筛查项目纳入了相当数量高于平均风险的个体,这些个体可能需要结肠镜检查而非粪便潜血检测筛查。其他参与者近期已进行过结肠镜检查,可能需要推迟筛查。基于大规模人群粪便潜血检测的筛查项目需要更有效地针对平均风险人群,并应将高风险或低风险人群转向更个体化的评估。